uniQure N.V.
▲ 0 upgrades / ▼ 1 downgrades / 2 reiterations from 3 firms
Nov 10, 2026 (14 days)
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 5, 2026 | Barclays | downgrade | Overweight → Equal-Weight | — | 53% |
| Oct 2, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Sep 30, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Jul 30, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jul 30, 2026 | Wolfe Research | upgrade | Peer Perform → Outperform | — | 54% |
| Jul 30, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jun 29, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 25, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jun 18, 2026 | Barclays | upgrade | Equal-Weight → Overweight | — | 53% |
| Jun 18, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Jun 18, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Jun 18, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| May 6, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 30, 2026 | Chardan Capital | maintain | Buy → Buy | — | 46% |
| Apr 20, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Mar 23, 2026 | Barclays | maintain | Equal-Weight → Equal-Weight | — | 53% |
| Mar 11, 2026 | Mizuho | upgrade | Neutral → Outperform | — | 52% |
| Mar 10, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 9, 2026 | Chardan Capital | maintain | Buy → Buy | — | 46% |
| Mar 9, 2026 | RBC Capital | upgrade | Sector Perform → Outperform | — | 55% |
| Mar 9, 2026 | Wells Fargo | upgrade | Equal-Weight → Overweight | — | 54% |
| Mar 3, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Mar 3, 2026 | Wells Fargo | downgrade | Overweight → Equal-Weight | — | 54% |
| Mar 3, 2026 | Chardan Capital | maintain | Buy → Buy | — | 46% |
| Mar 3, 2026 | Mizuho | downgrade | Outperform → Neutral | — | 52% |
| Mar 2, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Mar 2, 2026 | Cantor Fitzgerald | upgrade | Overweight → Neutral | — | 50% |
| Feb 24, 2026 | Wolfe Research | initiate | — → Peer Perform | $0 | 54% |
| Feb 10, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $70 | 44% |
| Feb 10, 2026 | HC Wainwright& Co. | reiterate | Buy → Buy | — | — |
| Jan 28, 2026 | Barclays | initiate | — → Equal-Weight | $31 | 53% |
| Dec 11, 2025 | Stifel | maintain | Buy → Buy | $40 | 53% |
| Dec 9, 2025 | Mizuho | maintain | Outperform → Outperform | $33 | 52% |
| Dec 4, 2025 | Chardan Capital | maintain | Buy → Buy | $53 | 46% |
| Nov 12, 2025 | Wells Fargo | maintain | Overweight → Overweight | $60 | 54% |
| Nov 11, 2025 | Chardan Capital | maintain | Buy → Buy | $53 | 46% |
| Nov 10, 2025 | Leerink Partners | maintain | Outperform → Outperform | $60 | 51% |
| Nov 4, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $38 | 54% |
| Nov 4, 2025 | RBC Capital | maintain | Outperform → Outperform | $45 | 55% |
| Nov 4, 2025 | William Blair | downgrade | Outperform → Market Perform | $0 | 47% |
| Nov 4, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $70 | 44% |
| Nov 3, 2025 | Chardan Capital | maintain | Buy → Buy | $53 | 46% |
| Oct 6, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $110 | 44% |
| Oct 2, 2025 | Wells Fargo | maintain | Overweight → Overweight | $80 | 54% |
| Sep 25, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $56 | 54% |
| Sep 25, 2025 | Mizuho | maintain | Outperform → Outperform | $60 | 52% |
| Sep 25, 2025 | Wells Fargo | maintain | Overweight → Overweight | $65 | 54% |
| Sep 25, 2025 | Guggenheim | maintain | Buy → Buy | $95 | 52% |
| Sep 25, 2025 | Cantor Fitzgerald | maintain | Overweight → Overweight | $80 | 50% |
| Sep 25, 2025 | Chardan Capital | maintain | Buy → Buy | $76 | 46% |
No cross-platform signals in the last 90 days
Price targets, earnings estimates, and firm actions for this ticker — updated within the last 24 hours.
Subscribe for Full Access